Genialis is the RNA Biomarker company. We envision a world where precision medicine delivers the best possible outcomes for patients, families, and their communities. We achieve this by working with pharma companies developing the next generation of life-saving oncology drugs, partnering with diagnostics companies building new tests to inform treatment decisions, and collaborating with the world’s leading cancer research institutions. ResponderID™, Genialis’ machine-learning-driven disease modeling framework, delivers actionable biomarkers and optimally positions novel drugs to accelerate translational research, streamline drug development and ensure the best possible clinical care.